

MAR 02 2005

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)

ADDRESS TO: Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.: 04-1011-C Application No.: 10/763,904 USPTO Confirmation No.: 7766 Filing Date: January 23, 2004 First Named Inventor: Pascal Druzgala Group Art Unit: 1624 Examiner: Balasubramanian
---	--

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application to and including March 4, 2005.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):


<input checked="" type="checkbox"/> One Month (37 CFR 1.17(a)(1))	\$120.00
<input type="checkbox"/> Two Months (37 CFR 1.17(a)(2))	\$
<input type="checkbox"/> Three Months (37 CFR 1.17(a)(3))	\$
<input type="checkbox"/> Four Months (37 CFR 1.17(a)(4))	\$
<input type="checkbox"/> Five Months (37 CFR 1.17(a)(5))	\$

Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$200.00.

A check in the amount of the fee is enclosed.

The Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Deposit Account Number 13-2490. I have enclosed a duplicate copy of this sheet.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name	Michael S. Greenfield
Reg. No.	37,142
Signature	
Date	March 2, 2005


EXT (Rev. 1/30/01)

03/14/2005 GDUCKETT 00000006 132490 10763904

01 FC:1251 120.00 DA

[Page 1 of 1]

3-ethoxycarbonyl-4,6-dioxo-5-allyl-5-isopentylhexahydropyrimidine



, and pharmaceutically acceptable salts thereof.

Bullet 6.5

(new) A composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier or diluent.

Bullet 7.4

(new) A composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier or diluent.

Bullet 8.1

(new) A composition comprising the compound according to claim 4 and a pharmaceutically acceptable carrier or diluent.